Fluvastatin depresses the enhanced lipid peroxidation in vitamin E-deficient hamsters

References

• Halliwell B., Gutteridge J.M.C. Role of free radicals and catalytic metal ions in human disease: an overview. Methods in Enzymology 1990; 186: 1–85
   PubMed Web of Science ®Google Scholar
• Ames B.N., Shigenaga M.K., Hagen T.M. Oxidants, antioxidants, and the degenerative diseases of aging. Proceedings of the National Academy of Sciences of the United States of America 1993; 90: 7915–7922
   PubMed Web of Science ®Google Scholar
• Rice-Evans C.A., Diplock A.T. Current status of antioxidant therapy. Free Radical Biology and Medicine 1993; 15: 77–96
   PubMed Web of Science ®Google Scholar
• Daugherty A., Roselaar S.E. Lipoprotein oxidation as a mediator of atherogenesis: insights from pharmacological studies. Cardiovascular Research 1995; 29: 297–311
   PubMed Web of Science ®Google Scholar
• Ylä-Herttuala S., Palinski W., Rosenfeld M.E., Parthasarathy S., Carew T.E., Butler S., Witztum J.L., Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. Journal of Clinical Investigation 1989; 84: 1086–1095
   PubMed Web of Science ®Google Scholar
• Carew T.E., Schwenke D.C., Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proceedings of the National Academy of Sciences of the United States of America 1987; 84: 7725–7729
   PubMed Web of Science ®Google Scholar
• Langtry H.D., Markham A. Fluvastatin: a review of its use in lipid disorders. Drugs 1999; 57: 583–606
   PubMed Web of Science ®Google Scholar
• Suzumura K., Yasuhara M., Tanaka K., Suzuki T. Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro. Biochemical Pharmacology 1999; 57: 697–703
   PubMed Web of Science ®Google Scholar
• Suzumura K., Yasuhara M., Tanaka K., Odawara A., Narita H., Suzuki T. An in vitro study of the hydroxyl radical scavenging property of fluvastatin, an HMG-CoA reductase inhibitor. Chemical and Pharmaceutical Bulletin 1999; 47: 1010–1012
   PubMed Web of Science ®Google Scholar
• Suzumura K., Yasuhara M., Narita H. Superoxide anion scavenging properties of fluvastatin and its metabolites. Chemical and Pharmaceutical Bulletin 1999; 47: 1477–1480
   PubMed Web of Science ®Google Scholar
• Suzumura K., Odawara A., Yasuhara M., Tanaka K., Narita H., Suzuki T. In vitro inhibitory effects of the optical isomers and metabolites of fluvastatin on copper ion-induced LDL oxidation. Biological and Pharmaceutical Bulletin 1999; 22: 971–974
   PubMedGoogle Scholar
• Suzumura K., Tanaka K., Yasuhara M., Narita H. Inhibitory effects of fluvastatin and its metabolites on hydrogen peroxide-induced oxidative destruction of hemin and low-density lipoprotein. Biological and Pharmaceutical Bulletin 2000; 23: 873–878
   PubMedGoogle Scholar
• Tokumaru S., Ogino R., Shiromoto A., Iguchi H., Kojo S. Increase of lipid hydroperoxides in tissues of vitamin E-deficient rats. Free Radical Research 1997; 26: 169–174
   PubMed Web of Science ®Google Scholar
• Awad J.A., Morrow J.D., Hill K.E., Roberts L.J., II, Burk R.F. Detection and localization of lipid peroxidation in selenium- and vitamin E-deficient rats using F2-isoprostatnes. Journal of Nutrition 1994; 124: 810–816
   PubMed Web of Science ®Google Scholar
• Stein O., Dabach Y., Hollander G., Halperin G., Thiery J., Stein Y. Relative resistance of the hamster to aortic atherosclerosis in spite of prolonged vitamin E deficiency and dietary hypercholesterolemia. Putative effect of increased HDL?. Biochimica et Biophysica Acta 1996; 1299: 216–222
   PubMedGoogle Scholar
• Zwart L.L.D., Meerman J.H.N., Commandeur J.N.M., Vermeulen N.P.E. Biomarkers of free radical damage applications in experimental animals and in humans. Free Radical Biology and Medicine 1999; 26: 202–226
   PubMed Web of Science ®Google Scholar
• Patrono C., FitzGerald G.A. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arteriosclerosis Thrombosis and Vascular Biology 1997; 17: 2309–2315
   PubMed Web of Science ®Google Scholar
• Roberts L.J., II, Morrow J.D. The generation and actions of isoprostanes. Biochimica et Biophysica Acta 1997; 1345: 121–135
   PubMed Web of Science ®Google Scholar
• Pratico D., Tangirala R.K., Rader D.J., Rokach J., FitzGerald G.A. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in apo E-deficient mice. Nature Medicine 1998; 4: 1189–1192
   PubMed Web of Science ®Google Scholar
• Moore K., Roberts L.J., II. Measurement of lipid peroxidation. Free Radical Research 1998; 28: 659–671
   PubMed Web of Science ®Google Scholar
• Parker R.A., Sabrah T., Cap M., Gill B.T. Relation of vascular oxidative stress, α-tocopherol, and hyphercholesterolemia to early atherosclerosis in hamsters. Arteriosclerosis Thrombosis and Vascular Biology 1995; 15: 349–358
   PubMed Web of Science ®Google Scholar
• Mitani H., Bandoh T., Ishikawa J., Kimura M., Totsuka T., Hayashi S. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits. British Journal of Pharmacology 1996; 119: 1269–1275
   PubMedGoogle Scholar
• Buttriss J.L., Diplock A.T. High-performance liquid chromatography methods for vitamin E in tissues. Methods in Enzymology 1984; 105: 131–138
   PubMed Web of Science ®Google Scholar
• Kontush A., Spranger T., Reich A., Djahansouzi S., Karten B., Braesen J.H., Finckh B., Kohlschütter A., Beisiegel U. Whole plasma oxidation assay as a measure of lipoprotein oxidizability. Biofactors 1997; 6: 99–109
   PubMedGoogle Scholar
• Wolff S.P. Ferrous ion oxidation in the presence of ferric ion indicator xylenol orange for measurement of hydroperoxides. Methods in Enzymology 1994; 233: 182–188
   Web of Science ®Google Scholar
• Ohashi N., Yoshikawa M. Rapid and sensitive quantification of 8-iso-prostaglandin F2α in human plasma and urine by liquid chromatography-electrospray ionization-mass spectrometry. Journal of Chromatography B 2000; 746: 17–24
   PubMedGoogle Scholar
• Stadtman E.R. Protein oxidation and aging. Science 1992; 257: 1220–1224
   PubMed Web of Science ®Google Scholar
• Inoue M. Interorgan metabolism and membrane transport of glutathione and related compounds. Renal Biochemistry, R.K.H. Kinne. Elsevier, New York 1985; 225–269, In
   Google Scholar
• Suzumura K., Kasahara E., Wang Y., Chien K.C., Inoue M. Decreased turnovers of glutathione and ascorbic acid in Watanabe heritable hyperlipidemic rabbits. Journal of Nutritional Science and Vitaminology 2000; 46: 205–209
   PubMedGoogle Scholar
• Aviram M. Interaction of oxidized low density lipoprotein with macrophages in atherosclerosis, and the antiatherogenicity of antioxidants. European Journal of Clinical Chemistry Clinical Biochemistry 1996; 34: 599–608
   PubMedGoogle Scholar
• Aviram M., Hussein O., Rosenblat M., Schlezinger S., Hayek T., Keidar S. Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy. Journal of Cardiovascular Pharmacology 1998; 31: 39–45
   PubMed Web of Science ®Google Scholar
• Kleinveld H.A., Demacker P.N.M., De Haan A.F.J., Stalenhoef A.F.H. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. European Journal of Clinical Investigation 1993; 23: 289–295
   PubMedGoogle Scholar
• Salonen R., Nyyssönen K., Porkkala-Sarataho E., Salonen J.T. The Kuopio atherosclerosis prevention study (KAPS): Effects of pravastatin treatment on lipids, oxidation resistance of lipoproteins, and atherosclerotic progression. American Journal of Cardiology 1995; 76: 34C–39C
   Google Scholar
• Suzumura K., Kasahara E., Ohnishi Y., Chien K.C., Inoue M. Fluvastatin normalizes the decreased turnovers of glutathione and ascorbic acid in Watanabe heritable hyperlipidemic rabbits. Clinical and Experimental Pharmacology Physiology 2000; 27: 709–714
   PubMedGoogle Scholar
• Leonhardt W., Kurktschiev T., Meissner D., Lattke P., Abletshauser C., Weidinger G., Jacross W., Hanefeld M. Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals. European Journal of Clinical Pharmacology 1997; 53: 65–69
   PubMedGoogle Scholar
• Herd J.A., Ballantyne C.M., Farmer J.A., Ferguson J.J., III, Jones P.H., West M.S., Gould K.L., Gotto A.M., Jr. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (lipoprotein and coronary atherosclerosis study [LCAS]). American Journal of Cardiology 1997; 80: 278–286
   PubMed Web of Science ®Google Scholar